University Hospital of Bonn, Bonn, Germany.
Oregon Health and Science University, Portland, OR, USA.
Immunotherapy. 2022 Jan;14(1):5-14. doi: 10.2217/imt-2021-0224. Epub 2021 Nov 15.
Atopic dermatitis (AD, also called atopic eczema) is a long-term skin disease that causes intensely itchy, red skin. Healthcare providers can prescribe medicated creams and ointments to reduce the signs and symptoms of AD. However, these treatments are not always enough to provide relief. A new medicine called abrocitinib, which is taken every day as a tablet, reduces part of the body's immune response that happens in AD. The clinical study described in this plain language summary, called JADE COMPARE, investigated how well and how safely 16 weeks of treatment with abrocitinib worked in adults with AD compared to placebo ('dummy treatment') and a medicine that is already approved for AD, called dupilumab. The study showed that abrocitinib was better than placebo in improving the signs and symptoms of AD after 16 weeks. In addition, patients who were taking abrocitinib 200 mg for 2 weeks experienced greater relief from itch than patients who were taking abrocitinib 100 mg, placebo, or dupilumab. More people who took abrocitinib 200 mg reported side effects than those taking abrocitinib 100 mg, placebo, or dupilumab, but most of these side effects were mild or moderate. ClinicalTrials.gov NCT number: NCT03720470.
特应性皮炎（AD，也称为特应性湿疹）是一种长期的皮肤疾病，会导致皮肤剧烈瘙痒、发红。医疗保健提供者可以开一些药用乳膏和软膏来减轻 AD 的症状。然而，这些治疗方法并不总是足以缓解症状。一种名为阿布昔替尼的新药，每天作为片剂服用，可以减轻 AD 中发生的部分身体免疫反应。这项名为 JADE COMPARE 的临床研究用通俗易懂的语言总结了，研究了与安慰剂（“假治疗”）和一种已批准用于 AD 的药物（度普利尤单抗）相比，16 周的阿布昔替尼治疗在 AD 成人患者中的疗效和安全性如何。研究表明，阿布昔替尼在改善 AD 的症状方面优于安慰剂 16 周后。此外，接受阿布昔替尼 200mg 治疗 2 周的患者的瘙痒缓解程度大于接受阿布昔替尼 100mg、安慰剂或度普利尤单抗治疗的患者。服用阿布昔替尼 200mg 的患者比服用阿布昔替尼 100mg、安慰剂或度普利尤单抗的患者报告的副作用更多，但大多数副作用是轻度或中度的。ClinicalTrials.gov NCT number: NCT03720470。
